PMC9942507_01
Immunohistochemical staining by D5F3 (Ventana, Oro Valley, Arizona) shows diffuse expression of ALK in the cytoplasm of tumor cells (original magnification x100).
OTT-16-109-g0001.jpg
PMC9942507_01_OTT-16-109-g0001.jpg
f0001
ALK in the tumor tissue from the previous surgery (Figure 1). At the same time, the previous surgical tumor tissue was detected by NGS based on a pan-cancer 8-gene panel. ALK-LIMS1 was detected.
The novel LIMS1-ALK fusion. Sequencing reads of LIMS1 and ALK are shown by the Integrative Genomics Viewer.
OTT-16-109-g0002.jpg
PMC9942507_01_OTT-16-109-g0002.jpg
f0002
The ALK-LIMS1 was fused by intron 20 of ALK to intron 1 of LIMS1 and retained the promotor region and the entire intracellular kinase domain, respectively (Figure 2A and B).
Images of liver computed tomography (CT) scans of the patient before (A) and after (B) crizotinib.
OTT-16-109-g0003.jpg
PMC9942507_01_OTT-16-109-g0003.jpg
f0003
Two months later, the right upper lung lesion and liver (Figure 3) progressed and the left pleural and pelvic effusions appeared.
The timeline from diagnosis of NSCLC to different stages of therapeutic regime and tumor evaluation and death.
OTT-16-109-g0004.jpg
PMC9942507_01_OTT-16-109-g0004.jpg
f0004
The treatment timeline and tumor evaluation are presented in Figure 4.